BioXcel Therapeutics

11:15 AM - 11:30 AM (JST), Tuesday, March 5, 2019 ・ 2nd Floor
BioXcel Therapeutics, Inc. is a publicly traded clinical stage biotech company leveraging the power of Artificial Intelligence to advance the next wave of medicines, initially targeting oncology indications and CNS diseases. The company’s lead therapeutic candidates are BXCL501, a proprietary sublingual formulation of an anesthetic for the treatment of acute agitation, with the potential to expand into other neuropsychiatric and neurodegenerative disorders, and, BXCL701, a DPP8-9/FAP inhibitor with broad potential application in oncology indications, both as a monotherapy and in combination with immuno-oncology agents, and The company’s strategy is to apply a drug re-innovation approach to develop therapeutic candidates with a high probability of clinical and regulatory success more quickly and at a lower cost than traditional research and development approaches. Please visit for more information.
Company Type:
Publicly Traded Company
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Multiple Therapeutics
Lead Product in Development:
BXCL701, BXCL501
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided